AstraZeneca said an experimental cancer drug shrank tumors in half of patients in an early-stage study, a result that may help its case that Pfizer Inc.’s takeover bid substantially undervalues the company. Pasi Janne, professor of medicine at the Dana-Farber Cancer Institute, is the lead author of the study.
